InvestorsHub Logo
Post# of 252682
Next 10
Followers 6
Posts 703
Boards Moderated 0
Alias Born 09/23/2006

Re: None

Wednesday, 05/22/2013 8:37:09 AM

Wednesday, May 22, 2013 8:37:09 AM

Post# of 252682
NXTM: The behavior of this stock continues to impress me. When I posted last week, the share price was $12.50. It opens today at $13.50 with news that their vendor agreement with DaVita Healthcare has been extended and expanded:

http://finance.yahoo.com/news/nxstage-announces-agreements-davita-210900673.html

LAWRENCE, Mass., May 21, 2013 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading manufacturer of innovative dialysis products, today announced that it has entered into new agreements covering its supply of home, critical care and in-center products to DaVita, the kidney care division of DaVita Healthcare Partners Inc.

For the use of products for home hemodialysis in the United States, NxStage has executed a second amended and restated National Service Provider Agreement with DaVita (the "Home Agreement"). The Home Agreement continues, in all material respects, the terms of the first amended and restated National Service Provider Agreement between NxStage and DaVita dated July 22, 2010, with pricing for NxStage's products subject to System One™ home patient growth targets.

The term of the Home Agreement extends through December 31, 2015, and thereafter automatically extends on a monthly basis unless terminated by either party.

"We are delighted to continue working with DaVita to expand patient access to our life-changing therapy," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage Medical, Inc. "These agreements underscore the value and strength of NxStage's innovative technology and our commitment to delivering high quality products to our customers and their patients."

NxStage and DaVita also entered into an agreement covering the purchase of NxStage's System One and other products for acute inpatient therapy within the critical care market through December 31, 2015.

Lastly, NxStage's subsidiary, Medisystems, and DaVita extended the term of their Needle Purchase Agreement dated January 6, 2008 through at least December 31, 2014, although DaVita may by October 31, 2013 elect to extend this to December 31, 2015.

AJ
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.